SYSTM Wealth Solutions LLC Purchases 12,180 Shares of Natera, Inc. (NASDAQ:NTRA)

SYSTM Wealth Solutions LLC grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 3,592.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,519 shares of the medical research company’s stock after buying an additional 12,180 shares during the quarter. SYSTM Wealth Solutions LLC’s holdings in Natera were worth $1,356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. E Fund Management Co. Ltd. lifted its holdings in shares of Natera by 105.1% during the 2nd quarter. E Fund Management Co. Ltd. now owns 9,979 shares of the medical research company’s stock valued at $1,081,000 after buying an additional 5,113 shares during the period. Virtu Financial LLC lifted its holdings in shares of Natera by 20.1% during the 2nd quarter. Virtu Financial LLC now owns 9,288 shares of the medical research company’s stock valued at $1,006,000 after buying an additional 1,552 shares during the period. Edgestream Partners L.P. bought a new position in shares of Natera during the 2nd quarter valued at $2,359,000. Renaissance Technologies LLC lifted its holdings in shares of Natera by 8.2% during the 2nd quarter. Renaissance Technologies LLC now owns 216,500 shares of the medical research company’s stock valued at $23,445,000 after buying an additional 16,317 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Natera by 35.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company’s stock worth $28,680,000 after purchasing an additional 69,523 shares during the period. 99.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. TD Cowen raised their target price on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Robert W. Baird raised their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Canaccord Genuity Group raised their target price on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Morgan Stanley raised their target price on Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $120.07.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 37,500 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $108.10, for a total transaction of $4,053,750.00. Following the completion of the transaction, the chief executive officer now owns 213,351 shares in the company, valued at $23,063,243.10. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Steven Leonard Chapman sold 37,500 shares of Natera stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $108.10, for a total value of $4,053,750.00. Following the completion of the transaction, the chief executive officer now owns 213,351 shares in the company, valued at $23,063,243.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of Natera stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. The disclosure for this sale can be found here. Insiders sold a total of 86,197 shares of company stock worth $9,561,358 over the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Natera Trading Down 1.9 %

Shares of Natera stock opened at $127.21 on Wednesday. The firm has a market cap of $15.62 billion, a price-to-earnings ratio of -40.77 and a beta of 1.53. The business has a 50-day moving average price of $113.49 and a 200-day moving average price of $104.74. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $132.01.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.97) earnings per share. Equities research analysts anticipate that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.